Adaptive Biotechnologies Corporation
ADPT
$19.66
-$0.06-0.30%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 252.75M | 205.22M | 189.53M | 178.96M | 177.28M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 252.75M | 205.22M | 189.53M | 178.96M | 177.28M |
| Cost of Revenue | 32.63M | 31.14M | 33.68M | 34.75M | 26.10M |
| Gross Profit | 220.12M | 174.07M | 155.85M | 144.20M | 151.18M |
| SG&A Expenses | 162.87M | 159.25M | 156.10M | 157.57M | 160.57M |
| Depreciation & Amortization | 1.70M | 1.70M | 1.70M | 1.70M | 1.70M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 330.94M | 326.33M | 325.71M | 334.30M | 344.43M |
| Operating Income | -78.19M | -121.11M | -136.19M | -155.34M | -167.15M |
| Income Before Tax | -79.60M | -121.24M | -141.89M | -159.60M | -195.35M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -79.60 | -121.24 | -141.89 | -159.60 | -195.35 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -17.00K | 8.00K | 55.00K | 103.00K | 104.00K |
| Net Income | -79.61M | -121.23M | -141.84M | -159.49M | -195.24M |
| EBIT | -78.19M | -121.11M | -136.19M | -155.34M | -167.15M |
| EBITDA | -60.10M | -102.84M | -117.41M | -136.09M | -146.95M |
| EPS Basic | -0.53 | -0.81 | -0.96 | -1.09 | -1.34 |
| Normalized Basic EPS | -0.34 | -0.52 | -0.58 | -0.66 | -0.72 |
| EPS Diluted | -0.54 | -0.82 | -0.96 | -1.09 | -1.34 |
| Normalized Diluted EPS | -0.35 | -0.52 | -0.58 | -0.66 | -0.72 |
| Average Basic Shares Outstanding | 601.39M | 596.47M | 591.80M | 588.40M | 585.62M |
| Average Diluted Shares Outstanding | 612.12M | 596.47M | 591.80M | 588.40M | 585.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |